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ABSTRACT
Spontaneous bacterial peritonitis (SBP) is a severe complication in patients with cirrhosis and ascites. It is
predominantly caused byEscherichia coli. The phylogenetic group andvirulence genotype ofE. coli isolates
causing SBPwere investigated, and the association of these characteristics with host factors and prognosis
was examined. Seventy-six episodes of E. coli SBP that occurred over a 9-year period were studied. The
phylogenetic group of the isolates and the presence of 36 virulence factor genes were investigated. The
inﬂuence of bacterial and host factors on in-hospitalmortalitywas assessed bymultiple logistic regression.
Phylogenetic groups A, B1, B2 and D were found in 26%, 4%, 46% and 24% of the isolates, respectively.
Virulence factor genesweremore frequent in B2 isolates than in non-B2 isolates (mean virulence score 15.4
vs. 7.3, p <10)4). Ciproﬂoxacin resistance was signiﬁcantly associated with non-B2 groups and a low
virulence score. Host factors independently associated with a shift from B2 to non-B2 isolates were
norﬂoxacinprophylaxis (OR 13.01, p 0.0213) andprothrombin ratio (OR 1.04 for a 10%decrease, p 0.0211).
The model for end-stage liver disease (MELD) score (OR 1.83, p 0.0007) and hospital-acquired SBP
(OR 4.13, p 0.0247) were independent predictors of in-hospital mortality. In contrast, outcome was not
inﬂuenced by the phylogenetic group or the virulence proﬁle. These ﬁndings indicate that the
characteristicsofE. coli isolates causingSBPvarywith theseverityof liverdiseaseandwithﬂuoroquinolone
prophylaxis. Host factors are more important than bacterial factors in predicting in-hospital mortality.
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INTRODUCTION
Spontaneous bacterial peritonitis (SBP) is a severe
complication in patients with cirrhosis and ascites
[1]. The 1-year probability of developing SBP for a
cirrhotic patient with ascites is approximately
10%, but it is signiﬁcantly increased in speciﬁc
subgroups of high-risk patients, namely those
who have survived a previous episode, those with
low ascitic ﬂuid protein levels and those with
gastrointestinal haemorrhage [2–5]. The in-hospi-
tal mortality rate associated with SBP is 20–30%
and is mostly related to the development of renal
impairment [6–8]. Moreover, survival expectancy
for those who recover is short, the 6-month
probability of survival being 40–50% [9,10].
SBP is most often caused by intestinal organ-
isms that translocate through the mucosal barrier
to the mesenteric lymph nodes, enter the blood-
stream and reach the ascitic ﬂuid [1,11]. The most
frequent organisms causing SBP are Gram-nega-
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tive bacilli of the Enterobacteriaceae family,
particularly Escherichia coli, which is isolated from
50–70% of bacteriologically documented episodes
[9,12,13]. However, the characteristics and viru-
lence factors (VFs) of E. coli strains isolated from
patients with SBP, and their potential role in the
pathogenesis and prognosis of this infection, have
not yet been investigated.
Phylogenetic studies have shown that E. coli
populations consist of different lineages segregat-
ing into four main phylogenetic groups, desig-
nated A, B1, B2 and D [14]. Most extra-intestinal
E. coli infections are caused by B2 strains, which
harbour a wide array of VF genes [15,16]. In
contrast, isolates of groups A and B1 contain few
virulence determinants and are usually regarded
as commensals. However, recent studies have
suggested that B2 strains are predominant in the
human resident intestinal ﬂora, whereas A and B1
strains are mostly transient strains [17,18]. Various
VFs associated with extra-intestinal E. coli infec-
tions have been described, including adhesins,
toxins and siderophores [19]. Previous studies
investigating the phylogenetic background and
the virulence proﬁle of E. coli concerned mostly
urinary isolates or blood isolates from patients
with diverse-source bacteraemias [17,19–22].
The aims of the present study were to analyse
the phylogenetic group, VF gene proﬁle and
susceptibility pattern of E. coli isolates causing
SBP in cirrhotic patients, and to examine the
relationship among these characteristics, host
factors and prognosis.
MATERIALS AND METHODS
Selection of SBP episodes
The database ﬁles of the Department of Microbiology and the
medical records of patients were reviewed in order to identify
episodes of E. coli SBP that occurred in cirrhotic patients in
Beaujon hospital over a 9-year period (1997–2005). SBP was
deﬁned by a positive culture from ascitic ﬂuid (AF) and an AF
polymorphonuclear neutrophil (PMN) cell count ‡250 ⁄mm3 in
the absence of an intra-abdominal source of infection [1].
Patients with secondary peritonitis were excluded from the
study. SBP was considered to be community-acquired
when diagnosed within the ﬁrst 48 h of hospitalization, and
hospital-acquired when diagnosed after this period. Overall,
165 SBP episodes were documented over the study period.
E. coli accounted for 76 (46%) of these episodes. The 76
episodes occurred in 72 patients, four of whom had two
consecutive episodes. Fifty-two episodes (68.4%) were
community-acquired and 24 episodes (31.6%) were hospital-
acquired. In 29 cases (35.5%), E. coli was also recovered from
blood cultures.
Microbiological studies
During the studyperiod,AFwasobtainedbyparacentesis, anda
10-mL sample was aseptically inoculated at the bedside into
each of a set of aerobic and anaerobic blood culture bottles. The
blood culture system used was BioArgos (Bio-Rad, Marnes-la-
Coquette, France) untilAugust 2003, andBactAlert (bioMe´rieux,
Marcy-l’e´toile, France) from September 2003 onwards. Bottles
were incubated at 37C for a period of 5 days. E. coli was
identiﬁed by the API20E strip system (bioMe´rieux). Antibiotic
susceptibility was tested by the Mueller–Hinton agar diffusion
method. The production of extended-spectrum b-lactamasewas
detected by the double-disk synergy test between disks of third-
generation cephalosporins and a clavulanic acid-containing
disk [23]. All isolates were kept frozen at )70C until subcul-
tured for the purpose of this study.
The phylogenetic group of the isolates was determined by a
triplex PCR-based method previously described by Clermont
et al. [24]. Isolates were tested for the presence of genes
encoding 36 extra-intestinal VFs with the use of PCR and dot
blot assays as described elsewhere [19–21,25]. The VF genes
studied included 14 adhesins (papAH, papC, papEF, papG,
sfa ⁄ foc, afa ⁄ dra, afaE8, iha, bmaE, gafD, F17, clpG, ﬁmH, hra), nine
toxins (hlyA, hlyF, cnf1, cdtB, sat, pic, vat, tsh, astA), four
siderophores (iroN, fyuA, ire, iutA) and nine protectins ⁄ inva-
sins (kpsM II, kpsMT III, rfc, cvaC, usp, traT, ibeA, ompT, iss).
The VF score of each isolate was calculated as the number of
VF genes for which the isolate tested positive [19].
Host factors
The following clinical and laboratory data were retrieved from
the medical ﬁles: age, sex, aetiology of cirrhosis, presence of
hepatocellular carcinoma, previous episode of SBP, norﬂoxacin
prophylaxis, prothrombin ratio, serum bilirubin, creatinine
and sodium levels, platelet count, international normalized
ratio, PMN count in the blood and in the AF, AF total protein
level, treatment, 15-day mortality and in-hospital mortality.
The model for end-stage liver disease (MELD) score was
calculated using the following formula: MELD = 3.78 loge
(bilirubin mg ⁄dL) + 11.2 loge (international normalized
ratio) + 9.57 loge (creatinine mg ⁄dL).
During the study period, empirical treatment of SBP was
started with amoxycillin–clavulanate or cefotaxime when the
PMN count in AF was ‡250 ⁄mm3. Antibiotic treatments were
subsequently adapted according to susceptibility results. From
2000 onwards, patients with SBP also received intravenously a
20% solution of human albumin, as described elsewhere [8].
Statistical analysis
Differences in continuous covariates between phylogenetic
groups (B2 vs. non-B2) were tested using the Wilcoxon test.
The relationship between phylogenetic groups and discrete
covariates was tested using Fisher’s exact test. The relationship
between the VF score and discrete and continuous covariates
was tested using the Wilcoxon test and the Spearman corre-
lation, respectively. Factors related to an infection with a B2
isolate vs. a non-B2 isolate on the one hand and prognostic
factors for in-hospital mortality on the other hand were tested
using univariate logistic regression (PROC LOGISTIC, SAS
9.0). Factors with p <0.2 in the univariate analysis were
entered into the multivariate model, which was reﬁned using
a backward procedure. The model was considered to be ﬁnal
when all factors had a p-value inferior to 0.05.
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RESULTS
Host factors
The clinical and laboratory characteristics of the
patients are shown in Table 1.
Phylogenetic groups and virulence genotypes
Phylogenetic groups A, B1, B2 and D were found
in 26%, 4%, 46% and 24% of the isolates,
respectively. The group distribution was similar
in community-acquired episodes and hospital-
acquired episodes of SBP. The most prevalent VF
genes were ﬁmH (93.4%), fyuA (69.7%), ompT
(68.4%), kpsM II (63.2%), iutA (56.6%) and traT
(56.6%). In contrast, some adhesin genes were
detected in none of the isolates (afa ⁄ dra, F17) or in
a single isolate (gafD, clpG). The mean VF score
was 11 (range 0–20). Most VF genes from each of
the four categories occurred more frequently in B2
isolates than in A, B1 or D isolates (Table 2). The
most signiﬁcant differences in prevalence favour-
ing B2 vs. non-B2 isolates were observed for papG
(71.4% vs. 14.6%), hlyA (51.4% vs. 2.4%), cnf1
(48.6% vs. 0%), vat (94.3% vs. 4.9%), fyuA (97.1%
vs. 46.3%), usp (97.1% vs. 7.3%) and ompT (100%
vs. 41.5%). As a result, the mean score was
signiﬁcantly higher in B2 isolates than in non-B2
isolates (15.4 vs. 7.3, p <10)4).
Resistance to antibiotics
The overall rates of resistance to amoxycillin,
amoxycillin–clavulanate, cefotaxime, co-trimox-
azole and ciproﬂoxacin were 47.4%, 14.5%,
3.9%, 30.3% and 15.8%, respectively. None of
the isolates produced an extended-spectrum
b-lactamase. As expected, ﬂuoroquinolone resis-
tance was signiﬁcantly higher in patients with
norﬂoxacin prophylaxis than in those without
prophylaxis (70% vs. 7.6%, p <10)4).
There was a strong association between phylo-
genetic group, virulence genotype and resistance
to ﬂuoroquinolones. None of the ciproﬂoxacin-
resistant isolates belonged to group B2, whereas
this group was predominant for ciproﬂoxacin-
susceptible isolates (Table 3). The rate of cipro-
ﬂoxacin resistance was signiﬁcantly higher in
non-B2 isolates than in B2 isolates (29.3% vs.
0%, p <0.001). Most VF genes were more frequent
in ciproﬂoxacin-susceptible isolates than in cipro-
ﬂoxacin-resistant isolates (Table 3). As a result,
the mean VF score was signiﬁcantly higher in
ciproﬂoxacin-susceptible isolates than in cipro-
ﬂoxacin-resistant isolates (11.6 vs. 7.7, p 0.026). In
contrast, the phylogenetic origin and the VF score
did not differ according to susceptibility to
b-lactams or co-trimoxazole (data not shown).
Table 1. Characteristics of patients
Characteristic Value
Epidemiological features
Age (years) 54.7 ± 10.6
Male gender 60 (78.9)
Alcoholism 46 (63)
Viral hepatitis 19 (36)
Carcinoma 11 (14.5)
Previous SBP episode 14 (18.4)
Norﬂoxacin prophylaxis 10 (13.2)
MELD score 27.9 ± 9.7
Blood variables
PMN (cells ⁄mm3) 8850 ± 5989
Platelet (cells ⁄mm3) 117 000 ± 85 618
Prothrombin ratio (%) 35.9 ± 15.6
Bilirubin (lmol ⁄L) 188 ± 138
Creatinine (lmol ⁄L) 163 ± 140
Sodium (mmol ⁄L) 131 ± 5.6
Ascitic ﬂuid variables
PMN (cells ⁄mm3) 4451 ± 4720
Total protein (g ⁄L) 10.4 ± 5.1
Data are means ± SD or numbers (%) of patients.
SBP, spontaneous bacterial peritonitis; PMN polymorphonuclear neutrophils;
MELD, model for end-stage liver disease.
Table 2. Virulence factor (VF) scores according to phylo-
genetic groups
Category
(no. of genes tested)
Mean VF score
Group A
(n = 20)
Group B1
(n = 3)
Group B2
(n = 35)
Group D
(n = 18)
Total
(n = 76)
Adhesins (14) 2.8 1.3 5.2 3.2 3.9
Toxins (9) 0.7 1 2.9 1 1.8
Siderophores (4) 1.3 1.7 2.7 1.9 2.1
Protectins ⁄ invasins (9) 1.2 2 4.6 2.8 3.2
Overall VF score 6.1 6 15.4 8.9 11
Data are mean number of VF genes per isolate.
Table 3. Prevalence of phylogenetic groups and virulence
factor (VF) scores in relation to susceptibility to ciproﬂox-
acin
Value in the indicated group
Ciproﬂoxacin-
susceptible
isolates (n = 64)
Ciproﬂoxacin-
resistant
isolates (n = 12)
Phylogenetic group
A 13 (20.3) 7 (58.3)
B1 2 (3.1) 1 (8.3)
B2 35 (54.7) 0
D 14 (21.9) 4 (33.3)
Mean VF scores
Adhesins 4.1 3.2
Toxins 2 0.9
Siderophores 2.2 1.7
Protectin ⁄ invasins 3.4 1.9
Overall VF score 11.6 7.7
Data are number (%) of isolates or mean number of VF genes per isolate.
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Relationship between bacterial and host factors
No association was found between phylogenetic
background and age, gender, origin of cirrhosis,
hepatocellular carcinoma and MELD score. When
compared to those with B2 isolates, patients with
non-B2 isolates more often had a history of
previous SBP (p 0.02), were more frequently
receiving norﬂoxacin prophylaxis (p 0.02) and
tended to have a lower prothrombin ratio
(p 0.06) and a lower platelet count (p 0.08)
(Table 4). The two groups of patients did not
differ signiﬁcantly with regard to other biological
variables. The seven variables with p <0.2 (previ-
ous SBP, norﬂoxacin prophylaxis, MELD score,
prothrombin ratio, platelet count, AF protein level
and positive blood cultures) were tested by
multiple logistic regression analysis. The only
host factors independently associated with non-
B2 isolates were norﬂoxacin prophylaxis
(OR 13.01, p 0.02) and the prothrombin ratio
(OR 1.04 for a 10% decrease, p 0.02).
Prognosis
Data on outcome were not available for three
episodes, as the patient was transferred to another
hospital. Two further episodes were excluded
from the outcome analysis because the patient
underwent liver transplantation during hospital-
ization. Among the 71 remaining episodes, 27
(38%) patients died within 2 weeks of SBP, and 38
(53.5%) patients died during hospitalization. The
time from SBP to death ranged from 1 to 50 days.
The inﬂuence of both bacterial and host factors
on in-hospital mortality were investigated by
univariate and multivariate analysis (Table 5).
Factors associated with mortality in the univariate
analysis were higher MELD score (p <0.01), lower
prothrombin ratio (p £0.01), higher bilirubin level
(p 0.04), higher creatinine level (p 0.01) and hos-
pital-acquired SBP (p <0.01). In contrast, outcome
was not related to phylogenetic group, virulence
score or antibiotic resistance. Five variables with
p <0.2 (MELD score, blood PMN, co-trimoxazole
resistance, hospital-acquired SBP, positive blood
cultures) were tested in a multivariate analysis.
Variables that are components of the MELD score
or closely related to these components, i.e. pro-
thrombin ratio, serum bilirubin and serum creat-
inine, were not included in the model. Multiple
logistic regression identiﬁed the MELD score
(OR 1.83 for an increase of 5, 95% CI 1.29–2.59,
p <0.01) and hospital-acquired SBP (OR 4.13,
95% CI 1.20–14.21, p 0.02) as independent pre-
dictors of in-hospital mortality.
Table 4. Comparison of host factors in patients with B2
isolates and those with non-B2 isolates
Variable
Value in the indicated group
Patients with
B2 isolates
(n = 35)
Patients with
non-B2 isolates
(n = 41) p
Age (years) 54.7 54.8 –a
Male gender 26 (74.3) 34 (82.9) –
Alcoholism 22 (64.7) 25 (64.1) –
Viral hepatitis 8 (23.5) 11 (28.2) –
Hepatocellular carcinoma 7 (20) 4 (9.7) –
Previous SBP episode 2 (5.7) 12 (29.3) 0.02
Norﬂoxacin prophylaxis 1 (2.9) 9 (21.9) 0.02
MELD score 26.1 29.3 0.19
Blood neutrophils (cells ⁄mm3) 10 752 7931 –
Platelet (cells ⁄m3) 136 828 100 049 0.08
Prothrombin ratio (%) 39.9 32.6 0.06
Serum bilirubin (lmol ⁄L) 200.3 177.5 –
Serum creatinine (lmol ⁄L) 142.4 181.5 –
Serum sodium (lmol ⁄L) 130.8 131.9 –
AF neutrophils (cells ⁄mm3) 4389 4501 –
AF protein (g ⁄L) 11.3 9.5 0.11
Hospital-acquired SBP 11 (31.4) 16 (39) –
Positive blood cultures 9 (25.7) 15 (36.6) 0.15
Data are no (%) of patients or mean value.
SBP, spontaneous bacterial peritonitis; AF, ascitic ﬂuid; MELD, model for end-stage
liver disease.
ap ‡0.2.
Table 5. Unvariate analysis of host and bacterial factors
associated with in-hospital mortality
Variable
Value in the indicated group
Patients
who died
(n = 38)
Patients who
survived
(n = 33) p
Age (years) 51.7 53 –a
Male gender 31 (81.6) 25 (75.7) –
Alcoholism 21 (58.3) 22 (68.7) –
Viral hepatitis 10 (27.8) 8 (25) –
Hepatocellular carcinoma 6 (15.8) 5 (15.1) –
Previous SBP episode 5 (13.2) 8 (24.2) –
Norﬂoxacin prophylaxis 3 (7.9) 6 (18.2) –
MELD score 31.6 23.1 <0.01
Blood neutrophils (cells ⁄mm3) 10 293 7850 0.12
Platelet (cells ⁄mm3) 117 552 114 180 –
Prothrombin ratio (%) 31.1 42.2 <0.01
Serum bilirubin (lmol ⁄L) 227.2 153.3 0.04
Serum creatinine (lmol ⁄L) 201.7 112.6 <0.01
Serum sodium (lmol ⁄L) 130.9 131.9 –
AF neutrophils (cells ⁄mm3) 4992 4181 –
AF protein (g ⁄L) 10.4 9.7 –
B2 group 16 (48.1) 17 (51.5) –
Virulence factor score 10 12 –
Amoxycillin resistance 21 (55.3) 14 (42.4) –
Amoxycillin–clavulanate resistance 5 (13.2) 5 (15.1) –
Cefatoxime resistance 1 (2.6) 1 (3) –
Ciproﬂoxacin resistance 5 (13.2) 6 (18.2) –
Co-trimoxazole resistance 14 (36.8) 7 (21.2) 0.16
Hospital-acquired SBP 16 (42.1) 7 (21.2) <0.01
Positive blood cultures 16 (42.1) 8 (24.2) 0.12
Appropriate empirical antibiotics 33 (94.3) 30 (96.7) –
Albumin therapy 9 (23.7) 11 (33.3) –
Data are no. (%) of patients or mean value.
SBP, spontaneous bacterial peritonitis; AF, ascitic ﬂuid; MELD, model for end-stage
liver disease.
ap ‡0.2.
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DISCUSSION
The intestinal ﬂora plays a key role in the
pathogenesis of SBP [26]. For a given bacterial
species, the difference between commensal status
and pathogenic status results from a balance
between the immune defences of the host and the
presence of VFs in the strain [15]. Thus, SBP
results from the translocation of intestinal bacteria
and the failure of the immune system to clear
these bacteria before they reach the AF. Whereas
host factors predisposing to the development of
SBP are well known, the role of bacterial factors
has not been investigated so far. The phylogenetic
group and virulence genotype of E. coli isolates
have been shown to play a major role in other
types of extra-intestinal infection, such as urinary
tract infection, neonatal meningitis and bactera-
emia [19,20,27]. In the present study, we deter-
mined the characteristics of 76 E. coli isolates from
cirrhotic patients with SBP and examined associ-
ations between bacterial traits and host factors.
These results indicate that E. coli SBP is caused
by isolates belonging, in decreasing order of
frequency, to groups B2, A, D and B1. Although
group B2 was the most common group, it
accounted for fewer than half of the isolates and
was therefore less predominant than previously
reported in urinary or bloodstream isolates from
non-immunocompromised patients [17,19,21].
The presence of VF genes was highly variable in
these isolates, with a VF score ranging from 0 to
20. As previously reported, most VF genes were
strongly associated with group B2 [19,21].
This group exhibited a score signiﬁcantly great-
er than that of the three other groups, whereas
groups A and B1 had the lowest prevalence of VF
genes. There was no relationship between resis-
tance to amoxycillin or co-trimoxazole, and phy-
logenetic origin, or VF proﬁle. In contrast,
ciproﬂoxacin resistance was signiﬁcantly associ-
ated with non-B2 groups and with a low VF score.
This ﬁnding is consistent with those of other
studies that, likewise, found a negative association
between virulence and resistance to quinolones in
E. coli [21,28]. The predominance of non-B2 groups
among ciproﬂoxacin-resistant isolates may indi-
cate greater capacities for mutation to resistance or
greater exposure to selection pressure among these
groups. Alternatively, foodborne transmission of
these isolates from quinolone-exposed poultry to
humans has been suggested [21].
In order to gain insights into the host–pathogen
relationship, associations between bacterial char-
acteristics and host factors were examined. As B2
isolates differed signiﬁcantly from A, B1 and D
isolates in their virulence and susceptibility pro-
ﬁle, patients with B2 isolates were compared to
those with non-B2 isolates. For this purpose, a
multiple logistic regression model was used to
differentiate between the respective inﬂuence of
closely related host factors (e.g. previous SBP and
prophylaxis). The results indicate that norﬂoxacin
prophylaxis and, to a lesser extent, decreased
prothrombin ratio are independently associated
with a shift from B2 to non-B2 isolates.
Prophylaxis is recommended in patients who
survived a ﬁrst episode, as they have a 50–70%
1-year probability of a further episode [5]. Several
studies have indicated that SBP caused by quino-
lone-resistant E. coli is unusual in these patients,
despite the emergence of resistant isolates in the
stools [29,30]. To explain this ﬁnding, it has been
suggested that quinolone-resistant isolates may
be less likely to translocate, either because of
lower pathogenicity or because of interference of
subinhibitory concentrations of norﬂoxacin with
VFs [29,31]. Other studies, however, found a high
prevalence of infections caused by quinolone-
resistant Gram-negative bacilli in patients receiv-
ing prophylaxis [12,31]. In the present study,
15.8% of E. coli SBP episodes were caused by
ciproﬂoxacin-resistant isolates, and these epi-
sodes were strongly associated with norﬂoxacin
administration. More interestingly, prophylaxis
was associated with a shift from the highly
virulent B2 group to less virulent non-B2 groups.
The prevalence of non-B2 isolates increased with
the severity of liver disease, although with a much
lower OR than that associated with prophylaxis.
Patients with advanced cirrhosis have impaired
immune defences, such as altered phagocytic
activity of neutrophils or deﬁcient opsonization
capacity of the AF. Thus, E. coli VFs present in B2
isolates may be essential for overcoming immune
defences in patients with moderately severe liver
disease. In contrast, these VFs may become less
necessary as liver dysfunction advances and host
defences weaken, thereby explaining the signiﬁ-
cant association between non-B2 isolates and
decreased prothrombin ratio. Hepatic function is
usually worse in patients receiving norﬂoxacin
than in those without prophylaxis [12]. Thus,
these ﬁndings suggest that ﬂuoroquinolone-resis-
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tant non-B2 isolates emerging in the intestinal
ﬂora following norﬂoxacin exposure may cause
SBP despite their poor VF arsenal in patients with
advanced liver disease. This result is consistent
with previous reports indicating that B2 isolates
are more frequent in immunocompetent patients
than in immunocompromised patients [32,33].
SBP is associated with high in-hospital mortal-
ity [8,13]. The development of renal failure, which
occurs in approximately 30% of patients with
SBP, is the strongest predictor of a fatal outcome
[6,7,31]. Poorer outcome is also associated with
the severity of liver disease [7,31]. However,
previous studies investigating SBP prognosis
were based only on host factors and did not
examine the potential role of microbial character-
istics, in particular virulence determinants. Exper-
imental studies in non-cirrhotic animals suggest
that VFs of E. coli isolates contribute to the
development of septic shock, acute renal failure
and lethality [34–38]. The role of both host factors
and bacterial factors in the outcome of E. coli SBP
were therefore evaluated by logistic regression
analysis.
The mortality rate was 37% within 2 weeks of
SBP and 53.7% during hospitalization, reﬂecting
the severity of disease in patients referred to the
transplant centre. Multivariate analysis identiﬁed
the MELD score as an independent predictor of in-
hospital mortality. In contrast, outcome was not
inﬂuenced by phylogenetic background, virulence
proﬁle and antibiotic susceptibility. Thus, the
present results indicate that host factors, namely
the severity of renal and hepatic dysfunction,
outweigh bacterial factors in predicting SBP in-
hospitalmortality. These ﬁndings are in agreement
with those of previous studies in patients without
cirrhosis, where the underlying condition was
more important than microbial factors in deter-
mining the outcome of E. coli bacteraemia
[22,37,38]. The hospital-acquired origin of SBP
was also predictive of in-hospital mortality.
Similarly, Fernandez et al. reported a higher mor-
tality rate in cirrhotic patients with nosocomial
infection than in those with community-acquired
infection [12]. The greater severity of disease in
patients with hospital-acquired SBP cannot totally
account for this ﬁnding, as nosocomial infection
was associated with death independently of the
MELD score by multivariate analysis.
In conclusion, E. coli isolates causing SBP
in cirrhotic patients are characterized by diversity
in their phylogenetic background and virulence
genotype. The genetic group of these isolates varies
with the severity of liver disease and with the
administration of norﬂoxacin prophylaxis. Non-B2
isolates, which harbour fewer virulence genes and
are more often resistant to ﬂuoroquinolones than
B2 isolates, are associated with norﬂoxacin pro-
phylaxis and with more advanced liver disease.
Host factors are more informative than bacterial
factors in predicting in-hospital mortality.
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